evekhm/cms_iom_500 huggingface dataset:
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58318)
KimmtrakAntineoplasticFDAHLA - A81381, 81374carbamazepineTegretolAnticonvulsantCPIC/FDAHLA - B81381, 81374carbamazepine, fosphenytoin, oxcarbazepine, phenytoinTegretol, Cerebyx, Trileptal, DilantinAnticonvulsantCPIC/FDAHLA - B81381, 81374pazopanibVotrientAntineoplasticFDAHLA - B81381, 81374abacavirZiagenAntiretroviral; HIVCPIC/FDAHLA - B81381, 81374allopurinolAloprim, ZyloprimHyperuricemiaCPIC/FDAHLA - DQA181377, 81383lapatinibTykerbAntineoplasticFDAHLA - DRB181377, 81383lapatinibTykerbAntineoplasticFDARYR181406desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholineSuprane, Ethrane, Fluothane, Forane, Penthrox, Ultane, Anectine, QuelicinVolatile anestheticCPICCoveredmultigene panels with intended usesPanels with a specific intended use such as major depressive disorder (MDD) or neuropsychiatric must include relevant ICD-10 codes.ICD-10 codes associated with intended usesIntended UseICD-10 codesDescriptionMDDF32.1Major depressive disorder, single episode, moderateMDDF32.2Major depressive disorder, single episode, severe without psychotic featuresMDDF32.3Major depressive disorder, single episode, severe with psychotic featuresMDDF32.4Major depressive disorder, single episode, in partial remissionMDDF33.1Major depressive disorder, recurrent, moderateMDDF33.2Major depressive disorder, recurrent severe without psychotic featuresMDDF33.3Major depressive disorder, recurrent, severe with psychotic symptomsMDDF33.41
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58318)
Major depressive disorder, recurrent, moderateMDDF33.2Major depressive disorder, recurrent severe without psychotic featuresMDDF33.3Major depressive disorder, recurrent, severe with psychotic symptomsMDDF33.41Major depressive disorder, recurrent, in partial remissionNeuropsychiatricF20.0Paranoid schizophreniaNeuropsychiatricF20.1Disorganized schizophreniaNeuropsychiatricF20.2Catatonic schizophreniaNeuropsychiatricF20.3Undifferentiated schizophreniaNeuropsychiatricF20.5Residual schizophreniaNeuropsychiatricF20.81Schizophreniform disorderNeuropsychiatricF20.89Other schizophreniaNeuropsychiatricF31.0Bipolar disorder, current episode hypomanicNeuropsychiatricF31.11Bipolar disorder, current episode manic without psychotic features, mildNeuropsychiatricF31.12Bipolar disorder, current episode manic without psychotic features, moderateNeuropsychiatricF31.13Bipolar disorder, current episode manic without psychotic features, severeNeuropsychiatricF31.2Bipolar disorder, current episode manic severe with psychotic featuresNeuropsychiatricF31.31Bipolar disorder, current episode depressed, mildNeuropsychiatricF31.32Bipolar disorder, current episode depressed, moderateNeuropsychiatricF31.4Bipolar disorder, current episode depressed, severe, without psychotic featuresNeuropsychiatricF31.5Bipolar disorder, current episode depressed, severe, with psychotic featuresNeuropsychiatricF31.61Bipolar disorder, current episode mixed, mildNeuropsychiatricF31.62Bipolar disorder, current episode mixed, moderateNeuropsychiatricF31.63Bipolar disorder, current episode mixed, severe, without psychotic featuresNeuropsychiatricF31.64Bipolar disorder, current episode mixed, severe, with psychotic featuresNeuropsychiatricF31.71Bipolar disorder, in partial remission, most recent episode hypomanicNeuropsychiatricF31.73Bipolar disorder, in partial remission, most recent episode manicNeuropsychiatricF31.75Bipolar disorder, in partial remission, most recent episode depressedNeuropsychiatricF31.77Bipolar disorder, in partial remission, most recent episode mixedNeuropsychiatric
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58318)
NeuropsychiatricF31.75Bipolar disorder, in partial remission, most recent episode depressedNeuropsychiatricF31.77Bipolar disorder, in partial remission, most recent episode mixedNeuropsychiatricF40.11Social phobia, generalizedNeuropsychiatricF41.0Panic disorder [episodic paroxysmal anxiety]NeuropsychiatricF41.1Generalized anxiety disorderNeuropsychiatricF41.3Other mixed anxiety disordersNeuropsychiatricF41.8Other specified anxiety disordersNeuropsychiatricF43.11Post-traumatic stress disorder, acuteNeuropsychiatricF43.12Post-traumatic stress disorder, chronicNeuropsychiatricF60.5Obsessive-compulsive personality disorderNeuropsychiatricF90.0Attention-deficit hyperactivity disorder, predominantly inattentive typeNeuropsychiatricF90.1Attention-deficit hyperactivity disorder, predominantly hyperactive typeNeuropsychiatricF90.2Attention-deficit hyperactivity disorder, combined typeNeuropsychiatricF90.8Attention-deficit hyperactivity disorder, other type
Article - Billing and Coding: Colon Capsule Endoscopy (CCE) (A58321)
CMS National Coverage PolicyTitle XVIII of the Social Security Act, 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim42 CFR410.32(d)(3) Claims review42 CFR414.50 Physician or other supplier billing for diagnostic tests performed or interpreted by a physician who does not share a practice with the billing physician or other supplierArticle TextThe information in this article contains billing, coding or other guidelines that complement the Local Coverage Determination (LCD) for Colon Capsule Endoscopy (CCE) L38755.Coding GuidanceNotice:It is not appropriate to bill Medicare for services that are not covered (as described by the related LCD) as if they are covered. When billing for non-covered services, use the appropriate modifier.For the purposes of this Article, ICD-10-CM codeZ53.8indicates that the instrument colonoscopy has been attempted and was incomplete andZ53.09indicates the procedure is contraindicated when a board certified or board eligible gastroenterologist, a surgeon trained in endoscopy, or a physician with equivalent endoscopic training determined from an evaluation of the patient that optical colonoscopy cannot be safely attempted.Documentation RequirementsAll documentation must be maintained in the patient's medical record and made available to the contractor upon request.Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service[s]). The documentation must include the legible signature of the physician or non-physician practitioner responsible for and providing the care to the patient.The submitted medical record must support the use of the selected ICD-10-CM code(s). The submitted CPT/HCPCS code must describe the service performed.
Article - Billing and Coding: Magnetic Resonance Guided Focused Ultrasound Surgery System (MRgFUS) for the treatment of neurologic conditions (A58323)
CMS National Coverage PolicyLanguage quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the LCD Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See Section 1869(f)(1)(A)(i) of the Social Security Act.Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:Title XVIII of the Social Security Act (SSA):Section 1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.Section 1862(a)(1)(D) refers to limitations on items or devices that are investigational or experimental.Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.Article Text
Article - Billing and Coding: Magnetic Resonance Guided Focused Ultrasound Surgery System (MRgFUS) for the treatment of neurologic conditions (A58323)
Article TextThis article contains coding and other guidelines that complement the Local Coverage Determination (LCD)for Magnetic Resonance Guided Focused Ultrasound Surgery System (MRgFUS) for the treatment of neurologic conditions.Coding Information:Procedure codes may be subject to National Correct Coding Initiative (NCCI) edits or OPPS packaging edits. Refer to NCCI and OPPS requirements prior to billing Medicare.For services requiring a referring/ordering physician, the name and NPI of the referring/ordering physician must be reported on the claim.A claim submitted without a valid ICD-10-CM diagnosis code will be returned to the provider as an incomplete claim under Section 1833(e) of the Social Security Act.The diagnosis code(s) must best describe the patient's condition for which the service was performed. For diagnostic tests, report the result of the test if known; otherwise the symptoms prompting the performance of the test should be reported.CPT 0398T is inclusive of all radiological services performed. Thus billing for radiological services associated with the performance of 0398T is not appropriate and thus not allowed.Per the Medicare Physician Fee Schedule Relative Value File, co-surgery is not allowed.Coverage is limited to a place of service of a hospital or a hospital outpatient department.
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58324)
CMS National Coverage PolicyTitle XVIII of the Social Security Act, 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.Article TextThe information in this article contains billing, coding or other guidelines that complement the Local Coverage Determination (LCD) for MolDX: Pharmacogenomics Testing L38294.Relevant National Coverage Determinations (NCDs):NCD 90.1: Testing for CYP2C9 and VKORC1 for Warfarin dosage must adhere to the requirements set forth in this NCD.Relevant Articles:Billing and Coding: MolDX: Testing of Multiple Genes A57503Billing and Coding: MolDX: Repeat Germline Testing A58017Additional documentation requirements for coverage and billing:Performing providers are required to acquire and retain records of the drugs under consideration for use or in use by the ordering physician that necessitate the use of ordered test.MolDX may make available specific forms to assist with test Technical Assessments (TAs). Please follow the instructions on the MolDX website to assist with this process. If such forms are available that pertain to the test type in question, these forms are required for successful coverage determinations.Billing instructions:To report a pharmacogenomics testing service, please submit the following claim information:Select the appropriate CPTor PLA codeEnter 1 unit of service (UOS)Enter the appropriate DEX Z-Codeidentifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:Loop 2400 or SV101-7 for the 5010A1 837PBox 19 for paper claimEnter the appropriate DEX Z-Codeidentifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:Line SV202-7 for 837I electronic claimBlock 80 for the UB04 claim formSelect the appropriate ICD-10-CM code
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58324)
Line SV202-7 for 837I electronic claimBlock 80 for the UB04 claim formSelect the appropriate ICD-10-CM codeFor part B claims, the drug or drugs in consideration for use that require the use of the pharmacogenomics (PGx) test must be submitted in the applicable detail line 2400 loop. The character maximum for loop 2400 is 80. To prevent denials/rejects when indicating more than 80 characters, please indicate the required drug names first.If multiple drugs are being used/considered for the specified beneficiary on the claim, they should be added to the comment line separated by a "_" (example Drug 1_Drug 2). Do not list the same drug more than once. The use of the generic name is strongly preferred. For Part B paper claims, the drug or drugs in consideration for use that require the use of the pharmacogenomics (PGx) test must be submitted in Item 19 field.Only one test may be performed per date of service; the test should be the most likely to identify the necessary alleles/variants for the drug/drugs in question. This applies to both single gene tests and multigene panels.The medical necessity for the additional testing and the clinical decision making for the additional testing must be documented in the medical record. The CPT code set relevant to this policy is listed in the table below. If no CPT code is available for the gene being tested, the NOC code 81479 may be used. The identification of the proper recommended billing code is established as part of the test application process.Gene/CPT coding/Drug informationTable 1 represents relevant gene/drug associations related to metabolizing enzymes from CPIC and FDA sources.Table 1.This table represents metabolism gene/drug associations from CPIC and FDA sources.GeneCPT Code(s)Generic NameTrade Name(s)Intended use for Drug(s)GuidanceABCG281479rosuvastatinCrestorAntihyperlipidemicCPICBCHE81479mivacurium, succinylcholineMivacurium chloride, AnectineNeuromuscular blocking agentFDACYP2B681479efavirenzSustivaAntiretroviral; HIVCPIC/FDACYP2B681479sertralineZoloft
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58324)
Neuromuscular blocking agentFDACYP2B681479efavirenzSustivaAntiretroviral; HIVCPIC/FDACYP2B681479sertralineZoloftAntidepressant-Selective Serotonin Reuptake Inhibitor (SSRI)CPIC/FDACYP2C1981225brivaracetam, clobazamBriviact, OnfiAnticonvulsantFDACYP2C1981225citalopram, escitalopram, sertralineCelexa, Lexapro, ZoloftAntidepressant - Selective Serotonin Reuptake Inhibitor (SSRI)CPIC/FDACYP2C1981225amitriptyline, clomipramine, doxepin, imipramine, trimipramineElavil, Anafranil, Silenor, Tofranil, SurmontilAntidepressant - TricyclicCPICCYP2C1981225voriconazoleVfendAntifungalCPIC/FDACYP2C1981225belzutifanWeliregAntineoplasticFDACYP2C1981225flibanserinAddyiMixed serotonin agonistFDACYP2C1981225clopidogrelPlavixPlatelet aggregation inhibitorCPIC/FDACYP2C1981225dexlansoprazole, lansoprazole, omeprazole, pantoprazoleDexilant, Prevacid, Prilosec, ProtonixProton Pump Inhibitor (PPI)CPIC/FDACYP2C1981225abrocitinibCibinqoSelective ImmunosuppressantFDACYP2C981227warfarinJantoven, CoumadinAnticoagulantCPIC/FDACYP2C981227fosphenytoin, phenytoinCerebyx, DilantinAnticonvulsantCPIC/FDACYP2C981227dronabinolMarinol, SyndrosAntiemeticFDACYP2C981227nateglinideStarlixAntihyperglycemicFDACYP2C981227
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58324)
81227dronabinolMarinol, SyndrosAntiemeticFDACYP2C981227nateglinideStarlixAntihyperglycemicFDACYP2C981227fluvastatinLescolAntihyperlipidemicCPICCYP2C981227erdafitinibBalversaFGFR kinase inhibitor, bladder cancerFDACYP2C981227siponimodMayzentMultiple sclerosisFDACYP2C981227celecoxib, flurbiprofen, lornoxicam, meloxicam, piroxicam, tenoxicamCelebrex, Ansaid, Ocufen, Chlortenoxicam, Xefo, Mobic, Vivlodex, Anjeso, Qmiiz ODT, Feldene, MobiflexNon-steroidal anti-inflammatory (NSAID)CPIC/FDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076UcarvedilolCoregAlpha - Beta blockerFDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076UpropafenoneRythmolAntiarrhythmicFDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076Ufluvoxamine, paroxetine, venlafaxine, vortioxetineLuvox, Paxil, Effexor XR, Brintellix, TrintellixAntidepressant  Selective Serotonin Reuptake Inhibitor (SSRI)CPIC/FDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58324)
CPIC/FDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076Uamitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, trimipramineElavil, Anafranil, Norpramin, Silenor, Tofranil, Aventyl, Pamelor, SurmontilAntidepressant - TricyclicCPICCYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076Umeclizine, ondansetron, tropisetronAntivert, Zofran ODT, TropisetronAntiemeticCPIC/FDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076Ugefitinib, tamoxifenIressa, Soltamox, NolvadexAntineoplasticCPIC/FDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076Uaripiprazole, aripiprazole lauroxil, brexpiprazole, clozapine, iloperidone, perphenazine, pimozide, thioridazineAbilify, Aristada, Rexulti, Clozaril, FazaClo, Versacloz, Fanapt, Trilafon, Orap, MellarilAntipsychoticFDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076Uamphetamine, atomoxetineAdzenys ER, Dyanavel XR, Adderall, StratteraAttention Deficit - Hyperactivity (ADHD) TherapyCPIC/FDACYP2D6
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58324)
amphetamine, atomoxetineAdzenys ER, Dyanavel XR, Adderall, StratteraAttention Deficit - Hyperactivity (ADHD) TherapyCPIC/FDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076UmetoclopramideReglanGastrointestinal prokinetic agentFDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076UeliglustatCerdelgaGaucher's diseaseFDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076Udeutetrabenazine, tetrabenazineAustedo, XenazineMovement disorder therapyFDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076UpitolisantWakixNarcolepsy therapy agentFDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076Ucodeine, oliceridine, tramadolOlinvyk, UltramOpioidCPIC/FDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076UlofexidineLucemyraOpioid withdrawalFDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076UcevimelineEvoxacSaliva stimulantFDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076UtolterodineDetrolUrinary antispasmodicFDA
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58324)
tolterodineDetrolUrinary antispasmodicFDACYP2D681226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076UvalbenazineIngrezzaVMAT2 inhibitorFDACYP3A581231tacrolimusPrografAntirejectionCPIC/FDACYP4F281479warfarinJantoven, CoumadinAnticoagulantCPIC/FDADPYD81232capecitabine, fluorouracilXeloda, Adrucil, Efudex, Fluoroplex, TolakAntineoplasticCPIC/FDAIFNL381283peginterferon alfa - 2a, peginterferon alfa - 2bPegasys, Pegasys ProClick, PegIntron, SylatronAntiviral, HCVCPICNAT281479procainamideProcan, PronestylAntiarrhythmicFDANAT281479sulfamethoxazole / trimethoprimBactrimAntibacterialFDANAT281479isoniazidNiazidAntitubercularFDANAT281479sulfasalazineAzulfidineDisease-Modifying Antirheumatic Drug (DMARD): Other - inflammatory bowel agentFDANAT281479amifampridine, amifampridine phosphateRuzurgi, FirdapseMultiple sclerosisFDANUDT1581306azathioprine, mercaptopurine, thioguanineAzasan, Purixan, TabloidAntineoplasticCPIC/FDASLCO1B181328simvastatin, atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatinFloLipid, Zocor, Lipitor, Lescol, Mevacor, Altoprev, Altocor, Livalo, Zypitamag, Pravachol, CrestorAntihyperlipidemicCPIC/FDATPMT81335, 0034U, 0286U
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58324)
AntihyperlipidemicCPIC/FDATPMT81335, 0034U, 0286Uazathioprine, mercaptopurine, thioguanineAzasan, Purixan, TabloidAntineoplasticCPIC/FDAUGT1A181350belinostat, irinotecan, nilotinib, pazopanib, Sacituzumab Govitecan-HziyBeleodaq, Camptosar, Tasigna, Votrient, TrodelvyAntineoplasticFDAUGT1A181350atazanavirReyatazAntiretroviral, HIVCPICUGT2B1781479belzutifanWeliregAntineoplasticFDAVKORC181355warfarinJantoven, CoumadinAnticoagulantCPIC/FDATable 2 represents other relevant gene/drug associations that are not related to metabolism from CPIC and FDA sources.Table 2.This table represents other relevant therapeutic gene/drug associations from CPIC and FDA sources.GeneCPT Code(s)Generic NameTrade Name(s)Intended use for Drug(s)GuidanceAPOE81401lecanemabLeqembiAlzheimers DiseaseFDACACNA1S81479desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholineSuprane, Ethrane, Fluothane, Forane, Penthrox, Ultane, Anectine, QuelicinVolatile anestheticCPICG6PD81247rasburicase, pegloticaseElitek, KrystexxaHyperuricemiaCPICG6PD81247dapsoneAccone, AvlosulfonAntibacterialCPICG6PD81247primaquine, tafenoquineJasoprim, ArakodaAntimalarialCPICHLA - A81381tebentafuspKimmtrakAntineoplasticFDAHLA - A81381, 81374carbamazepineTegretolAnticonvulsantCPIC/FDAHLA - B81381, 81374
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58324)
KimmtrakAntineoplasticFDAHLA - A81381, 81374carbamazepineTegretolAnticonvulsantCPIC/FDAHLA - B81381, 81374carbamazepine, fosphenytoin, oxcarbazepine, phenytoinTegretol, Cerebyx, Trileptal, DilantinAnticonvulsantCPIC/FDAHLA - B81381, 81374pazopanibVotrientAntineoplasticFDAHLA - B81381, 81374abacavirZiagenAntiretroviral; HIVCPIC/FDAHLA - B81381, 81374allopurinolAloprim, ZyloprimHyperuricemiaCPIC/FDAHLA - DQA181377, 81383lapatinibTykerbAntineoplasticFDAHLA - DRB181377, 81383lapatinibTykerbAntineoplasticFDARYR181406desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholineSuprane, Ethrane, Fluothane, Forane, Penthrox, Ultane, Anectine, QuelicinVolatile anestheticCPICCoveredmultigene panels with intended usesPanels with a specific intended use such as major depressive disorder (MDD) or neuropsychiatric must include relevant ICD-10 codes.Test NameCompanyIntended UseGenesightAssurex HealthMajor Depressive Disorder (MDD) or NeuropsychiatricGenomind Professional PGx ExpressGenomind, Inc.NeuropsychiatricNeuroIDgenetixAltheaDxMajor Depressive Disorder (MDD) or NeuropsychiatricNeuropharmagenPrecision Molecular SolutionsNeuropsychiatricPGXPSYCHPHD Laboratory LLCNeuropsychiatricPsychotropic Pharmacogenomics Gene PanelMayo Clinic LaboratoriesNeuropsychiatricICD-10 codes associated with intended usesIntended UseICD-10 codesDescriptionMDDF32.1Major depressive disorder, single episode, moderateMDDF32.2
Article - Billing and Coding: MolDX: Pharmacogenomics Testing (A58324)
ICD-10 codes associated with intended usesIntended UseICD-10 codesDescriptionMDDF32.1Major depressive disorder, single episode, moderateMDDF32.2Major depressive disorder, single episode, severe without psychotic featuresMDDF32.3Major depressive disorder, single episode, severe with psychotic featuresMDDF32.4Major depressive disorder, single episode, in partial remissionMDDF33.1Major depressive disorder, recurrent, moderateMDDF33.2Major depressive disorder, recurrent severe without psychotic featuresMDDF33.3Major depressive disorder, recurrent, severe with psychotic symptomsMDDF33.41Major depressive disorder, recurrent, in partial remissionNeuropsychiatricF20.0Paranoid schizophreniaNeuropsychiatricF20.1Disorganized schizophreniaNeuropsychiatricF20.2Catatonic schizophreniaNeuropsychiatricF20.3Undifferentiated schizophreniaNeuropsychiatricF20.5Residual schizophreniaNeuropsychiatricF20.81Schizophreniform disorderNeuropsychiatricF20.89Other schizophreniaNeuropsychiatricF31.0Bipolar disorder, current episode hypomanicNeuropsychiatricF31.11Bipolar disorder, current episode manic without psychotic features, mildNeuropsychiatricF31.12Bipolar disorder, current episode manic without psychotic features, moderateNeuropsychiatricF31.13Bipolar disorder, current episode manic without psychotic features, severeNeuropsychiatricF31.2Bipolar disorder, current episode manic severe with psychotic featuresNeuropsychiatricF31.31Bipolar disorder, current episode depressed, mildNeuropsychiatricF31.32Bipolar disorder, current episode depressed, moderateNeuropsychiatricF31.4Bipolar disorder, current episode depressed, severe, without psychotic featuresNeuropsychiatricF31.5Bipolar disorder, current episode depressed, severe, with psychotic featuresNeuropsychiatricF31.61Bipolar disorder, current episode mixed, mildNeuropsychiatricF31.62Bipolar disorder, current episode mixed, moderateNeuropsychiatricF31.63Bipolar disorder, current episode mixed, severe, without psychotic featuresNeuropsychiatricF31.64Bipolar disorder, current episode mixed, severe, with psychotic features